Cargando…
Cost–effectiveness thresholds: pros and cons
Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost–effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost–effectiveness thresholds allow cost–effectiveness ratios that...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Health Organization
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153921/ https://www.ncbi.nlm.nih.gov/pubmed/27994285 http://dx.doi.org/10.2471/BLT.15.164418 |
_version_ | 1782474792279998464 |
---|---|
author | Bertram, Melanie Y Lauer, Jeremy A De Joncheere, Kees Edejer, Tessa Hutubessy, Raymond Kieny, Marie-Paule Hill, Suzanne R |
author_facet | Bertram, Melanie Y Lauer, Jeremy A De Joncheere, Kees Edejer, Tessa Hutubessy, Raymond Kieny, Marie-Paule Hill, Suzanne R |
author_sort | Bertram, Melanie Y |
collection | PubMed |
description | Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost–effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost–effectiveness thresholds allow cost–effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization’s Commission on Macroeconomics in Health suggested cost–effectiveness thresholds based on multiples of a country’s per-capita gross domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have been used as decision rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level shows them to lack country specificity and this – in addition to uncertainty in the modelled cost–effectiveness ratios – can lead to the wrong decision on how to spend health-care resources. Cost–effectiveness information should be used alongside other considerations – e.g. budget impact and feasibility considerations – in a transparent decision-making process, rather than in isolation based on a single threshold value. Although cost–effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil society organizations and patient groups, and is transparent, consistent and fair. |
format | Online Article Text |
id | pubmed-5153921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | World Health Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-51539212016-12-19 Cost–effectiveness thresholds: pros and cons Bertram, Melanie Y Lauer, Jeremy A De Joncheere, Kees Edejer, Tessa Hutubessy, Raymond Kieny, Marie-Paule Hill, Suzanne R Bull World Health Organ Policy & Practice Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost–effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost–effectiveness thresholds allow cost–effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization’s Commission on Macroeconomics in Health suggested cost–effectiveness thresholds based on multiples of a country’s per-capita gross domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have been used as decision rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level shows them to lack country specificity and this – in addition to uncertainty in the modelled cost–effectiveness ratios – can lead to the wrong decision on how to spend health-care resources. Cost–effectiveness information should be used alongside other considerations – e.g. budget impact and feasibility considerations – in a transparent decision-making process, rather than in isolation based on a single threshold value. Although cost–effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil society organizations and patient groups, and is transparent, consistent and fair. World Health Organization 2016-12-01 2016-09-19 /pmc/articles/PMC5153921/ /pubmed/27994285 http://dx.doi.org/10.2471/BLT.15.164418 Text en (c) 2016 The authors; licensee World Health Organization. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL. |
spellingShingle | Policy & Practice Bertram, Melanie Y Lauer, Jeremy A De Joncheere, Kees Edejer, Tessa Hutubessy, Raymond Kieny, Marie-Paule Hill, Suzanne R Cost–effectiveness thresholds: pros and cons |
title | Cost–effectiveness thresholds: pros and cons |
title_full | Cost–effectiveness thresholds: pros and cons |
title_fullStr | Cost–effectiveness thresholds: pros and cons |
title_full_unstemmed | Cost–effectiveness thresholds: pros and cons |
title_short | Cost–effectiveness thresholds: pros and cons |
title_sort | cost–effectiveness thresholds: pros and cons |
topic | Policy & Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153921/ https://www.ncbi.nlm.nih.gov/pubmed/27994285 http://dx.doi.org/10.2471/BLT.15.164418 |
work_keys_str_mv | AT bertrammelaniey costeffectivenessthresholdsprosandcons AT lauerjeremya costeffectivenessthresholdsprosandcons AT dejoncheerekees costeffectivenessthresholdsprosandcons AT edejertessa costeffectivenessthresholdsprosandcons AT hutubessyraymond costeffectivenessthresholdsprosandcons AT kienymariepaule costeffectivenessthresholdsprosandcons AT hillsuzanner costeffectivenessthresholdsprosandcons |